ANTI-CD137 AND PD-1/PD-L1 ANTIBODIES IN ROUTE TOWARDS CLINICAL SYNERGY.

T-cell co-stimulation and co-inhibition can be exploited  by blocking and agonist monoclonal antibodies (mAbs) respectively. Both strategies can be synergistically combined in mouse models. Early clinical results from combinations of anti-PD-1 mAbs in conjunction with agonist anti-CD137 (4-1BB) mAbs show excellent safety and promising efficacy.

http://ift.tt/2wGu8Fz